
Thermo Fisher Scientific NAE1 Monoclonal Antibody (OTI1A8), TrueMAB
NAE1 단백질을 인식하는 Mouse monoclonal antibody (Clone OTI1A8). Western blot에 최적화되어 있으며, Human 시료에 반응. Lyophilized 형태로 공급되며, PBS buffer(pH 7.3, 8% trehalose) 포함. 연구용으로만 사용 가능.
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific NAE1 Monoclonal Antibody (OTI1A8), TrueMAB
Applications
- Western Blot (WB): Tested dilution 1:500
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Clone | OTI1A8 |
| Immunogen | Human recombinant protein fragment corresponding to amino acids 1–274 of human NAE1 produced in E. coli |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Concentration | 1 mg/mL |
| Purification | Affinity chromatography |
| Storage Buffer | PBS, pH 7.3, with 8% trehalose |
| Contains | No preservative |
| Storage Conditions | -20°C, Avoid freeze/thaw cycles |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
For reconstitution, add 100 µL distilled water to obtain a final antibody concentration of approximately 1 mg/mL.
For conjugation experiments using this carrier-free antibody, perform an additional desalting step (e.g., Zeba Spin Desalting Columns, 7K MWCO, 0.5 mL, Product #89882).
Target Information
The protein encoded by the NAE1 gene binds to the beta-amyloid precursor protein, which is a cell surface protein with signal-transducing properties and is implicated in the pathogenesis of Alzheimer’s disease.
This protein forms a heterodimer with UBE1C, binds and activates NEDD8 (a ubiquitin-like protein), and is required for cell cycle progression through the S/M checkpoint.
Three transcript variants encoding different isoforms have been identified for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
